Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xizang Haisco Pharma Invests in Regentis, an Israeli Device Maker

publication date: Feb 10, 2016
Xizang Haisco Pharma led a $15 million Series D funding for Regentis Biomaterials, an Israeli medical device company. As part of its investment, Haisco will own China rights to Regentis' lead product, GelrinC®, a proprietary hydrogel. Implanted as a liquid, GelrinC is cured in-situ via ultraviolet light to form a resorbable implant. Over time, the gel is gradually replaced by newly regenerated cartilage. Regentis plans to use the new capital to conduct US clinical trials of GenrinC. More details....

Stock Symbol: (SHZ: 002653)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital